Summary
This focused review examines two transcatheter approaches to treating severe tricuspid regurgitation: transcatheter edge-to-edge repair (T-TEER) and orthotopic transcatheter tricuspid valve replacement (TTVR). The authors synthesise recent clinical evidence, including the TRILUMINATE randomised trial, and provide a technical and anatomical framework to guide device selection. The review highlights that whilst T-TEER safely reduces regurgitation and improves health status, orthotopic TTVR shows promise for more complete tricuspid regurgitation elimination.
Regional applicability
Both T-TEER and TTVR are approved in Europe and the USA, making findings relevant to United Kingdom interventional cardiology practice. However, as this is a clinical cardiology review without agricultural or nutritional focus, its applicability to UK farming systems or food policy is not established.
Key measures
Tricuspid regurgitation reduction; health status outcomes; clinical efficacy; anatomic suitability for device selection
Outcomes reported
The review evaluates transcatheter tricuspid valve interventions (T-TEER and orthotopic TTVR) for treating severe tricuspid regurgitation, examining technical features, anatomic limitations, clinical data, and offering a framework for device selection.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.